Navigation Links
Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3
Date:5/11/2009

laborations with major pharmaceutical companies like Pfizer to co-develop PF-04523655 in DME, wet-AMD, and other potential ocular indications provides further credibility to our siRNA technology capabilities."

Jayakrishna Ambati M.D., Professor and Vice Chair, Department of Ophthalmology & Visual Sciences, University of Kentucky, member of Quark's Medical Advisory Board, and one of the authors on the study, stated, "My laboratory's research has shown that many siRNAs suppress neovascularization regardless of their sequences or targets and can have dangerous off target effects. For that reason, I'm gratified to see this research, suggesting that Quark is seeing success in developing siRNA compounds that are effective."

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to other target tissues including the eye, ear, lung, spinal cord and brain.

PF-04523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified siRNA designed to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-04523655 is licensed to Pfizer. In addition, Quark's current clinical pipeline includes QPI-1002, the first systemically administered siRNA drug in human clinical trials, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery and of delayed graft function in kidney transplantation. For the structure of these products Quark has licens
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
2. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
3. Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
4. Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
11. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... September 18, 2014 Bipartisan passage this ... bill designed to stimulate development and commercialization of new ... praised by leaders of SPIE, the international society ... American Manufacturing and Innovation (RAMI) Act, now moves to ... have said they are optimistic that it will win ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... near-patient testing, is performed outside a clinical laboratory. ... hence in administrating appropriate treatments and medication. POCT ... and prevalence of lifestyle diseases such as diabetes, ... and user-friendly. POCT devices are standardized to minimize ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 A novel ... an MRI scanner is currently being tested as part ... Women's Hospital in Boston with the aim of determining ... can make prostate cancer biopsies faster, more accurate, less ... system also has the potential to deliver prostate cancer ...
(Date:9/18/2014)... 18, 2014 ... ) has announced the addition of ... Strategic Business Report" report to ... report analyzes the worldwide markets for ... the following Product Segments: Polymeric Materials, ...
Breaking Biology Technology:House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 3POCT Market in China 2014-2018 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
...  Ambit Biosciences today announced that Michael A. Martino, Ambit,s president ... company and an update about its clinical development programs, including ... in New York City. , 14th Annual BIO ... on Monday, February 13, 2012 , Leerink Swann ...
... 9, 2012  Micross Components, a leading global provider ... to announce its participation in the "Drive for ... Electronics. Included as a "pit stop" during the ... selected because of its role in powering innovation ...
... Inc. (NYSE Amex: CUR ) announces that President ... BIO CEO & Investor Conference 2012 in New York City ... present a business overview, and an update on the company,s ... divisions. (Logo:  http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO ) ...
Cached Biology Technology:Ambit Biosciences to Present at Two Upcoming Investor Conferences 2Micross Components Hosts Stop on "Drive for Innovation" Tour 2Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012 2Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012 3
(Date:9/18/2014)... September 18, 2014 New research into the Crimean-Congo ... a severe hemorrhagic disease in humans similar to that ... for CCHFV infection. This discovery has the potential to ... pathogen. , The research, reported in a ... and conducted by scientists at the Texas Biomedical ...
(Date:9/18/2014)... foliage season that prompts millions of Americans to undertake jaunts ... possibly last a little longer within a century, according to ... in some areas of the United States as summer temperatures ... the journal Global Ecology and Biogeography . For instance, ... the state tree of New Hampshire could change color ...
(Date:9/18/2014)... 2014Many Americans across racial and ethnic groups describe ... on their day-to-day life, more so than other ... speech (57% of African-Americans, 49% of non-Hispanic whites, ... asked which disease or ailment is the worst ... among African-Americans followed by AIDS/HIV. Hispanics and ...
Breaking Biology News(10 mins):Research milestone in CCHF virus could help identify new treatments 2Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... person or set of identical twins. That makes them ... to international travel. But what happens when the tips ... ridges? It,s not the premise for a ... adermatoglyphia. It,s also known as "Immigration Delay Disease," because ...
... Scientists at the University of Plymouth have shown, for the ... effect on the brain and other parts of the central ... nanoparticles which are widely used as a whitening agent in ... applications being considered for the food industry. They found that ...
... common medicines on elderly people were widely reported earlier in the ... not appear to cause further cognitive impairment in those already suffering ... today by the journal Age and Ageing , Dr Chris ... a number of other universities and the NHS describe how they ...
Cached Biology News:Shake hands with the invisible man 2Reassurance for dementia sufferers on impact of common drugs 2
... Time-resolved microscopy is the ultimate tool for ... structures. Its applications previously have been limited ... microscope optics do not transmit in the ... in fluorescence spectroscopy, introduces a filter-based confocal ...
... G bind specifically to Fc regions of ... G conjugates are commonly used as affinity ... subtypes from serum, hybridoma ascites fluids, tissue ... reagents are also commonly used to capture ...
... quick (10 min) assay can detect H2O2 ... 10-acetyl-3,7-dihydroxyphenoxazine (ADHP). H2O2 oxidizes ADHP in a ... resorufin (excitation at 530-571 nm, emission at ... peroxidase in a one-step, homogeneous, no wash ...
... The Reverse-iT™ One-Step Kit is the ... in RT-PCR. It has been specifically ... The Reverse-iT™ One-Step Kit combines ... and ABgene®s Thermoprime Plus DNA Polymerase ...
Biology Products: